Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Engineered T cells: the promise and challenges of cancer immunotherapy.

Fesnak AD, June CH, Levine BL.

Nat Rev Cancer. 2016 Aug 23;16(9):566-81. doi: 10.1038/nrc.2016.97. Review.

2.

Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.

Krenciute G, Krebs S, Torres D, Wu MF, Liu H, Dotti G, Li XN, Lesniak MS, Balyasnikova IV, Gottschalk S.

Mol Ther. 2016 Feb;24(2):354-363. doi: 10.1038/mt.2015.199. Epub 2015 Oct 30.

3.

Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.

Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler JA, Portnow J, D'Apuzzo M, Forman SJ, Jensen MC.

Clin Cancer Res. 2015 Sep 15;21(18):4062-72. doi: 10.1158/1078-0432.CCR-15-0428. Epub 2015 Jun 9.

4.

Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.

Sengupta S, Thaci B, Crawford AC, Sampath P.

Biomed Res Int. 2014;2014:952128. doi: 10.1155/2014/952128. Epub 2014 Aug 27. Review.

5.

Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.

Mahadev V, Starr R, Wright SL, Martinez C, Jensen MC, Barish ME, Forman SJ, Brown CE.

PLoS One. 2014 May 2;9(5):e95123. doi: 10.1371/journal.pone.0095123. eCollection 2014.

6.

Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.

Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, Sengupta S.

Neuro Oncol. 2014 Oct;16(10):1304-12. doi: 10.1093/neuonc/nou045. Epub 2014 Apr 10. Review.

7.

Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis.

Brown CE, Warden CD, Starr R, Deng X, Badie B, Yuan YC, Forman SJ, Barish ME.

PLoS One. 2013 Oct 18;8(10):e77769. doi: 10.1371/journal.pone.0077769. eCollection 2013.

8.

The potential for genetically altered microglia to influence glioma treatment.

Li W, Holsinger RM, Kruse CA, Flügel A, Graeber MB.

CNS Neurol Disord Drug Targets. 2013 Sep;12(6):750-62. Review.

9.

Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy.

Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF.

J Neurooncol. 2013 Jan;111(2):103-11. doi: 10.1007/s11060-012-0998-x. Epub 2012 Nov 21.

10.

A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.

Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A.

Neuro Oncol. 2012 Oct;14(10):1239-53. Epub 2012 Sep 5.

11.

Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.

Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D'Apuzzo M, Barish ME, Forman SJ, Jensen MC.

Clin Cancer Res. 2012 Apr 15;18(8):2199-209. doi: 10.1158/1078-0432.CCR-11-1669. Epub 2012 Mar 8.

12.

Toxin-based targeted therapy for malignant brain tumors.

Chandramohan V, Sampson JH, Pastan I, Bigner DD.

Clin Dev Immunol. 2012;2012:480429. doi: 10.1155/2012/480429. Epub 2012 Feb 9. Review.

13.

A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.

Nakashima H, Terabe M, Berzofsky JA, Husain SR, Puri RK.

J Immunol. 2011 Nov 15;187(10):4935-46. doi: 10.4049/jimmunol.1102095. Epub 2011 Oct 17.

14.

Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.

Candolfi M, Kroeger KM, Xiong W, Liu C, Puntel M, Yagiz K, Muhammad AG, Mineharu Y, Foulad D, Wibowo M, Assi H, Baker GJ, Lowenstein PR, Castro MG.

Anticancer Agents Med Chem. 2011 Oct;11(8):729-38. Review.

15.

Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.

Nakashima H, Fujisawa T, Husain SR, Puri RK.

J Transl Med. 2010 Nov 10;8:116. doi: 10.1186/1479-5876-8-116.

16.

Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma.

Joshi BH, Puri RA, Leland P, Varricchio F, Gupta G, Kocak M, Gilbertson RJ, Puri RK; US Pediatric Brain Tumor Consortium.

Neuro Oncol. 2008 Jun;10(3):265-74. doi: 10.1215/15228517-2007-066. Epub 2008 Apr 22.

17.

Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas.

Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF.

J Neurooncol. 2008 Jul;88(3):245-50. doi: 10.1007/s11060-008-9566-9. Epub 2008 Mar 7.

18.

Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics.

Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-575. doi: 10.1158/1078-0432.CCR-06-1576.

Supplemental Content

Support Center